BioCryst Pharma

BIOCRYST PHARMACEUTICALS INC

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

bz_pharma_briefs

Biotech

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

BCRX

BioCryst&#39;s Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025.

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

movers

Intraday Update

Markets

AEMD

ARQT

AWIN

BOLT

BSFC

CABA

CDRO

CRKN

CSLR

CTNT

DELL

DLPN

EDBL

FFIE

GWAV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INTZ

IRBT

JFBR

KOSS

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MNDY

NOVA

NSYS

NTRB

NVAX

OPRX

PEGY

PLSE

PXLW

RIVN

RSKD

SINT

SLNA

SPCE

SPWR

VRPX

VTSI

YTEN

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

movers image

ARVN

CADL

CRML

FOUR

GDRX

JILL

NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharmaceuticals Inc

Press Releases

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

BioCryst to Present at Upcoming Investor Conferences

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

BioCryst to Present at Upcoming Investor Conference

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Ardelyx

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Beam Therapeutics

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Denali Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Galapagos NV - American Depositary Shares

Galapagos

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

MiMedx Group

Mesoblast Limited - American Depositary Shares

Mesoblast

MannKind

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Novavax

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Citizens Capital Markets

RBC Capital

HC Wainwright & Co.

JMP Securities

Evercore ISI Group

Comments

BioCryst Pharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga